Baird’s Jazz Pharmaceuticals JAZZ Stock Holding History

Baird’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$2.62M	Buy	15,142 +11,822	+356%	+$2.03M	0.03%	486
2014 Q4	$543K	Buy	+3,320	New	+$551K	0.01%	911
2014 Q3	–	Sell	-11,991	Closed	-$1.76M	–	1140
2014 Q2	$1.76M	Buy	+11,991	New	+$1.66M	0.02%	514

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

WBC

Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baird's JAZZ Position: Q1 2015 in Review

Baird increased its Jazz Pharmaceuticals (JAZZ) stake by 356% in Q1 2015, buying an estimated $2.03M and bringing the position to 15,142 shares worth $2.62M. The position accounts for 0.03% of the portfolio, ranked #486.

Baird first reported a position in JAZZ in Q2 2014 and has held it in 3 quarters since. 354 funds tracked by Wall St. Rank hold JAZZ as of Q1 2015.

Baird held 15,142 shares of Jazz Pharmaceuticals worth $2.62M as of Q1 2015.
Baird bought 11,822 Jazz Pharmaceuticals shares in Q1 2015, an estimated $2.03M.
Jazz Pharmaceuticals made up 0.03% of Baird's portfolio in Q1 2015, its #486 holding.
Baird first reported a position in Jazz Pharmaceuticals in Q2 2014 and has held it in 3 quarters since.
354 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.